Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR270773 emulsion for suspected or confirmed Gram-negative severe sepsis
2004-000406-51Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2004
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GR270773 in sepsis and Gram-negative bacterial infection (3 arms), sponsored by GSK. Primary endpoint: All-cause mortality at Day 28. Started Jun 2004; status: completed.
02
Drugs
GR270773
03
Conditions
sepsisGram-negative bacterial infection
Beyond the preview
Go deeper on 2004-000406-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000406-51.